Previous 10 | Next 10 |
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference...
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its boar...
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March. Aggressive selling on up and down days, with clear relative price weaknes...
Syndax Pharmaceuticals (SNDX) stock price fell 31% to $13.42 on April 20th, 2021 after reporting interim Phase 1 data on its genetically defined leukemia asset SNDX-5613. Investors seemed disappointed in the number of complete responses, some potential safety issues, and the specter o...
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2 nd Annual Virtual Oncology I...
For life sciences investors, the gene therapy market is one of the most interesting plays today. The US National Library of Medicine defines gene therapies as specialized treatments using genes for the prevention or treatment of disease. Gene therapies are designed to treat ...
Kura Oncology, Inc. (KURA) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Pete Spain - Vice President, Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Marc Grasso - Chief Financial Officer and Chief Business Off...
The following slide deck was published by Kura Oncology, Inc. in conjunction with this event. For further details see: Kura Oncology Investor Presentation - Slideshow
Image source: The Motley Fool. Kura Oncology, Inc. (NASDAQ: KURA) Q1 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Kura Oncology, Inc. (KURA) Q1 2021 Earnings Call Transcript
Kura Oncology (KURA): Q1 GAAP EPS of -$0.46 misses by $0.04. $603.9 million in cash, cash equivalents and investments provide runway into 2024.Press Release For further details see: Kura Oncology EPS misses by $0.04
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...